UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported): January 24, 2020
AYTU BIOSCIENCE, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-38247
|
47-0883144
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
373 Inverness Parkway, Suite 206
Englewood, CO 80112
(Address
of principal executive offices, including Zip Code)
Registrant’s
telephone number, including area code: (720) 437-6580
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common
Stock, par value $0.0001 per share
|
|
AYTU
|
|
The
NASDAQ Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security
Holders.
The
special meeting of stockholders for Aytu BioScience, Inc. (the
“Company”) was held on January 24, 2020. Of the
20,733,052 shares outstanding on the record date for the meeting, a
total of 16,679,856 shares were present or represented at the
meeting. The matters voted on as
described in the Company’s definitive proxy statement, as
filed on December 23, 2019, and the results of the votes are as
follows:
1.
The “Nasdaq
Rule 5635(d) Proposal” described in the Company’s
definitive proxy statement was approved with 9,173,191 votes in
favor, 267,716 votes against and 55,392 abstentions. The number of
broker non-votes was 7,183,557.
2.
The
“Conversion Proposal” described in the Company’s
definitive proxy statement was approved with 9,183,745 votes in
favor, 268,340 votes against and 44,214 abstentions. The number of
broker non-votes was 7,183,557.
3.
The
“Authorized Share Increase Proposal” described in the
Company’s definitive proxy statement was approved with
14,853,035 votes in favor, 1,755,451 votes against and 71,370
abstentions.
4.
The proposal to
approve the adjournment of the Special Meeting, if necessary, to
continue to solicit votes for the Nasdaq Rule 5635(d) Proposal and/or the Authorized
Share Increase Proposal was
approved with 14,984,656 votes in favor, 1,579,227 votes against
and 115,973 abstentions.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
AYTU
BIOSCIENCE, INC.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date:
|
January
24, 2019
|
|
By:
|
/s/
Joshua R. Disbrow
|
|
|
|
|
|
Joshua
R. Disbrow
|
|
|
|
|
|
Chief
Executive Officer
|
|
|
|
|
|
|